Literature DB >> 6668547

Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.

D J Swanson, D P Reitberg, I L Smith, P B Wels, J J Schentag.   

Abstract

Moxalactam pharmacokinetics at steady state was examined in a group of 40 patients with presumed or proven abdominal sepsis. Mean steady-state serum concentrations ranged from 27.0 to 211.0 mcg/ml and correlated inversely with creatinine clearance (r = 0.91, p less than 0.0001). Terminal half-life ranged from 1.27 to 8.27 hr and reflected the varying renal function of the patients. Moxalactam total body clearance (CL) displayed excellent correlation with creatinine clearance as 92% (r2 x 100) of the variance in clearance could be accounted for by renal function (p less than 0.0001). Pharmacokinetic parameters were estimated using noncompartmental analysis based on statistical moment theory. Noncompartmentally determined CL was in agreement with CL determined by nonlinear least squares regression (r = 0.99, p less than 0.0001). Moxalactam total body clearance is best predicted from creatinine clearance corrected for body surface area.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6668547     DOI: 10.1007/bf01058954

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  20 in total

1.  Rapid evaluation of creatinine clearance.

Authors:  K Siersbaek-Nielsen; J M Hansen; J Kampmann; M Kristensen
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

2.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

3.  Pharmacokinetics of moxalactam in patients with normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan; F C Luft
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

4.  Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.

Authors:  T Yoshida; S Matsuura; M Mayama; Y Kameda; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

Review 5.  Evaluation of moxalactam.

Authors:  M D Reed; J S Bertino; S C Aronoff; W T Speck; J L Blumer
Journal:  Clin Pharm       Date:  1982 Mar-Apr

6.  A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis.

Authors:  J J Schentag; P B Wels; D P Reitberg; P Walczak; J H Van Tyle; R J Lascola
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

7.  HPLC determination of D and L moxalactam in human serum and urine.

Authors:  J A Ziemniak; D A Chiarmonte; D J Miner; J J Schentag
Journal:  J Pharm Sci       Date:  1982-04       Impact factor: 3.534

8.  Steady-state moxalactam kinetics: comparisons with other cephalosporins.

Authors:  P Garzone; J Lyon; V L Yu; J Zuravleff; W Diven; W Pasculle
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

9.  Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

Authors:  W K Bolton; W M Scheld; D A Spyker; T L Overby; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

10.  Pharmacokinetics of moxalactam in patients with renal insufficiency.

Authors:  M Lam; C V Manion; A W Czerwinski
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

View more
  5 in total

Review 1.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

2.  Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.

Authors:  T E Jones; R W Milne; Y Mudaliar; L N Sansom
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

3.  Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients.

Authors:  R J Creger; R I Cowan; H S Nearman; J L Blumer; W R Selman; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

5.  Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.

Authors:  J I Schwartz; L E Jauregui; K A Bachmann; M E Martin; D P Reitberg
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.